



Social Services
and Seniors

Services sociaux
et des Aînés



PO Box 2000, Charlottetown
Prince Edward Island
Canada C1A 7N8

C.P. 2000, Charlottetown
Île-du-Prince-Édouard
Canada C1A 7N8

Memorandum / Note de service

To / Destinataire : All Retail Pharmacists and Staff

From / Expéditeur : Amanda Voutour

Date : August 2, 2010

Administrative Officer - Provincial Drug Programs

Tel / Tél : (902) 620-3288 Fax / Téléc : (902) 368-4905

Subject / Objet : Revised August 2010 Update to the Interchangeable / Maximum Allowable Cost List

E-mail / Courriel : advoutour@ihis.org

The August 2010 update to the PEI Drug Programs Interchangeable / Maximum Allowable Cost (MAC) List has been published. Changes in interchangeability will come into effect on the 16th August, 2010. Changes in pricing related to the addition of new interchangeable/MAC categories will come into effect on the 1st September, 2010.

Adobe Acrobat (pdf) and Excel versions of the complete list can be downloaded from the Government website at www.gov.pe.ca/health.

All product availability and pricing has been confirmed with manufacturers prior to publication of this update.

Please contact the Pharmacy Services Office at 368-4947 (Charlottetown) or 1-877-577-3737 (toll-free in PEI) if you are unable to access a copy of the list online.

Please note that the Maximum Allowable Cost List also contains products that although not listed in the Drug Programs Formulary but may be available through the Special Authorization (Exceptional Drug Request) Process. Refer to the Formulary to determine coverage of products under specific drug programs.

In addition, some of the Interchangeable / MAC Categories are only available through the Palliative Home Care Drug Pilot Project.

NEW INTERCHANGEABLE / MAC CATEGORIES

There are no changes to report.

PRODUCTS ADDED TO THE INTERCHANGEABLE / MAC LIST

The following products have been added to existing interchangeable categories:

APO-RISEDRONATE 35MG TABLETS	02353687
CO-VALACYCLOVIR 500MG TABLETS	02331748
JAMP-ROPINIROLE 0.25MG TABLETS	02352338
JAMP-ROPINIROLE 1MG TABLETS	02352346
JAMP-ROPINIROLE 2MG TABLETS	02352354
JAMP-ROPINIROLE 5MG TABLETS	02352362
JAMP-TAMSULOSIN 0.4MG CAPSULES	02352419
LETROZOLE 2.5MG TABLETS	02348969
MYLAN-CARVEDILOL 3.125MG TABLETS	02347512
MYLAN-CARVEDILOL 6.25MG TABLETS	02347520

MYLAN-CARVEDILOL 12.5MG TABLETS	02347555
MYLAN-CARVEDILOL 25MG TABLETS	02347571
MYLAN-LANSOPRAZOLE 15MG TABLETS	02353830
MYLAN-LANSOPRAZOLE 30MG TABLETS	02353849
PMS-FENTANYL MTX 12MCG/H	02341379
PMS-FENTANYL MTX 25MCG/H	02341387
PMS-FENTANYL MTX 50MCG/H	02341395
PMS-FENTANYL MTX 75MCG/H	02341409
PMS-FENTANYL MTX 100MCG/H	02341417
PMS-FINASTERIDE 5MG TABLETS	02310112
PMS-OMEPRAZOLE 20MG DR TABLETS	02310260
PMS-RISEDRONATE 35MG TABLETS	02302209
RATIO-RISEDRONATE 35MG TABLETS	02319861
SANDOZ-RISEDRONATE 35MG TABLETS	02327295

CHANGES TO MAC PRICES

RISEDRONATE	02246896	ACTONEL	PGA	<u>5.2277</u>
35MG TABLETS	02298392	NOVO-RISEDRONATE	NOP	<u>5.2277</u>
	02319861	RATIO-RISEDRONATE	RPH	<u>5.2277</u>
	02353687	APO-RISEDRONATE	APX	<u>5.2277</u>

DELETED INTERCHANGEABLE / MAC CATEGORIES

There are no deleted categories to report.

DISCONTINUED PRODUCTS

The following products have been removed from the Maximum Allowable Cost List. These products will not appear in the next publication of the Drug Programs Formulary, but will remain as benefits for the next twelve months.

CO-FLUCONAZOLE 150MG TABLETS	02323419
PMS-FLUOXETINE 4MG/ML ORAL SOLUTION	02177595
PMS-FOSINOPRIL 10MG TABLETS	02255944

CHANGE IN MANUFACTURER

There have been no changes in manufactures to report.

IMPORTANT NOTICES

Important DIS Notice: Prescriber ID Lists and DIS Information Bulletins

Effective immediately, updated physician identification number lists will be posted on the website. This will be updated monthly and are password protected. Follow the link:

<http://www.gov.pe.ca/health/index.php3?number=1026272&lang=E>
password: peipharm2010

Also, we have put together, as a result of feedback from the Benefit Evaluation, a Bulletin service aimed at end users of the DIS. The information will be largely based on features, upgrades and issues relating to the function of the DIS.

For reference, these bulletins can be found here:

<http://gov.pe.ca/health/disbulletins/>

